![OB GYN new masthead 1](https://prodcraftsa01.blob.core.windows.net/assets/products/ob-gyn-clinical-alert/_contentImage/OB_GYN_new_masthead_1.png)
OB/GYN Clinical Alert – March 1, 2019
March 1, 2019
View Issues
-
Brexanolone for Postpartum Depression: Promising, but Will It Deliver?
In two double-blind, randomized, placebo-controlled, Phase III trials of brexanolone, a new medicine for postpartum depression, researchers found a significant reduction in symptoms at 60 hours of infusion compared to placebo.
-
Perimenopausal Depression
OB/GYNs strive to screen women for perinatal depression both in pregnancy and postpartum. Although depression frequently affects reproductive-age women, it is common in women throughout the lifespan. This article discusses depression in perimenopausal women.
-
Ripples From Original WHI Study Results Continue: Is This Appropriate?
Recommendations for menopausal hormone therapy were widely publicized and adopted following the original publication of the results of the Women’s Health Initiative and affected both initiation and continuation of estrogen therapy through at least 2013.
-
Should Two-Dose Methotrexate Be the Standard of Care for Ectopic Pregnancy?
In this meta-analysis, the two-dose methotrexate treatment protocol was associated with higher odds of treatment success and a shorter treatment period compared to the single-dose protocol.
-
Welcome New Board Member